The Big4Bio Company to Watch Program
September 2021: Molecular Assemblies

THE COMPANY/THE MISSION Changing the Paradigm for Writing DNA Molecular Assemblies’ leaders detail how the company got started, the company’s technology for synthesizing DNA, and why that technology is better than current methods.     THE TECHNOLOGY Moving Synthetic Biology into the 21st Century A deeper look at the company’s enzymatic DNA synthesis technology, why […]

Read More

Sikich + Process Stream = Expanded Best of Breed Solutions Through a Company’s Journey

Sikich LLP is a 1000-member business advisory firm that offers ERP and CRM technology and accounting services to a broad array of companies, including life sciences, tailored to fit their specific needs. In April 2021, Sikich acquired Process Stream, a leader in digital transformation services for regulated industries, which includes life sciences. The acquisition expands Sikich’s offerings […]

Read More

The Big4Bio Company to Watch Program
July 2021: Meissa Vaccines

THE COMPANY/THE MISSION Meissa Vaccines Is Driven to Rid the World of Viral Respiratory Scourges Meissa Vaccines is on a mission to solve a puzzle that has eluded scientists for decades—a pediatric vaccine against respiratory syncytial virus, or RSV.     THE PIPELINE Building Single Dose, Intranasal Vaccines to Prevent COVID-19 and RSV Making vaccines […]

Read More

Spotlight: Mispro Biotech Services — Vivarium Services That Keep In Vivo Research In-House

Mispro Biotech Services is a contract vivarium organization (CVO) that operates a network of full-service coworking vivarium facilities in all major U.S. and Canadian biotech hubs where emerging and established biopharma companies can conduct and control their own in vivo studies. Along with offering access to state-of-the-art vivarium research space, Mispro supports its clients with comprehensive animal care […]

Read More

The Big4Bio Company to Watch Program
May 2021: Venatorx Pharmaceuticals

THE COMPANY/THE MISSION The Drug Hunter Flying Under the Radar In 2010, Drs. Christopher Burns, Daniel Pevear, and Luigi Xerri set out to build a company focused on anti-infectives; they named it Venatorx, which loosely translated means “Drug Hunter.”   THE PIPELINE Addressing the Next Pandemic: Superbugs Venatorx’s lead clinical-stage antibiotics address the growing problem […]

Read More

SPOTLIGHT: Big4Bio:Boston 2020 Year-in-Review

Welcome to the 2020 Big4Bio Year-in-Review for the Boston area! We hope you enjoy looking back on 2020’s top stories, deals, and M&A that went down in Greater Boston’s research, pharma, and biotech sectors as we head into 2021. Here’s what you’ll find inside the Year-in-Review 2020 report: Facts about Greater Boston’s life sciences industry […]

Read More

Spotlight Q&A: TFF Pharmaceuticals – Innovative Drug Formulation May Expand Geographic Reach of COVID-19 Vaccines and Treatments

LaVoieHealthScience Client Spotlight Following is a Q&A with Glenn Mattes, President, CEO and Director of TFF Pharmaceuticals (Nasdaq: TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing (TFF) technology platform. Welcome to Big4Bio, Mr. Mattes. Can you share with our readers what is important about […]

Read More

Spotlight Q&A: John Hallinan, Chief Development Officer, Danforth Advisors

John Hallinan is the newly-named Chief Development Officer of Danforth Advisors, the life science industry’s leading resource for operational accounting, finance support and strategic CFO advisory. He was previously Chief Business Officer at Massachusetts Biotechnology Council (MassBio), representing the world’s premier life sciences hub, where he led efforts to catalyze early-stage innovation. He has more […]

Read More

Spotlight Q&A: Outlook Therapeutics — Developing First Ophthalmic Formulation of Bevacizumab for FDA Approval

LaVoieHealthScience Client Spotlight Following is a Q&A with Lawrence Kenyon, President, CEO and CFO of Outlook Therapeutics (NASDAQ: OTLK), a late-stage clinical biotech company focused on developing the first FDA-approved ophthalmic formulation of bevacizumab-vikg to treat wet age-related macular degeneration (wet AMD) and other retinal diseases.  By way of background for our readers, age-related macular […]

Read More